Moleculin Biotech Inc (MBRX)

[cvinvestor]

Leave it there for tomorrow and I expect it will be filled. Company has stated on CC that the trials for primary drug candidate mentioned as having potential for lung cancer treatment is expected to go into 2020 for dosage alone, so while I'm hoping to get shares for LT at better price and recoup minor losses, there is nothing in the conference call to sustain a 60%-100% increase in price or valuation based on a new potential application of the drug that would have to gather more data before entering clinical trial stage.

What the CC reaffirmed is that the company seems to be cooking with gas and is making real progress on variable fronts and the data thus far is more than positive without any negative events.

Since the stock wasn't climbing and is expanding trials and expenses, I'm hoping to get more shares nearer to $1.00 than $2.00.